BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1351 related articles for article (PubMed ID: 12599224)

  • 21. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.
    Shaha AR
    Laryngoscope; 2004 Mar; 114(3):393-402. PubMed ID: 15091208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hurthle cell neoplasm of the thyroid gland.
    Ahmed M; Bin Yousef H; Greer W; Faraz H; Al Sobhi S; Al Zahrani A; Raef H; Al Ghamdi A; Al Kadhi Y; Al Dayel F
    ANZ J Surg; 2008 Mar; 78(3):139-43. PubMed ID: 18269475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.
    Kebebew E; Greenspan FS; Clark OH; Woeber KA; McMillan A
    Cancer; 2005 Apr; 103(7):1330-5. PubMed ID: 15739211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003.
    Mills SC; Haq M; Smellie WJ; Harmer C
    Eur J Surg Oncol; 2009 Mar; 35(3):230-4. PubMed ID: 18722077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.
    Zidan J; Karen D; Stein M; Rosenblatt E; Basher W; Kuten A
    Cancer; 2003 Mar; 97(5):1181-5. PubMed ID: 12599223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group.
    La Quaglia MP; Black T; Holcomb GW; Sklar C; Azizkhan RG; Haase GM; Newman KD
    J Pediatr Surg; 2000 Jun; 35(6):955-9; discussion 960. PubMed ID: 10873043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
    Podnos YD; Smith DD; Wagman LD; Ellenhorn JD
    J Surg Oncol; 2007 Jul; 96(1):3-7. PubMed ID: 17567872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical treatment of papillary and follicular thyroid carcinoma.
    Lin JD; Jeng LB; Chao TC; Weng HF; Huang HS
    Int Surg; 1996; 81(1):61-6. PubMed ID: 8803709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.
    Saad MF; Ordonez NG; Rashid RK; Guido JJ; Hill CS; Hickey RC; Samaan NA
    Medicine (Baltimore); 1984 Nov; 63(6):319-42. PubMed ID: 6503683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
    Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
    Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer.
    Kushchayeva Y; Duh QY; Kebebew E; D'Avanzo A; Clark OH
    Am J Surg; 2008 Apr; 195(4):457-62. PubMed ID: 18070728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
    Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
    Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
    Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
    Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.
    Haigh PI; Ituarte PH; Wu HS; Treseler PA; Posner MD; Quivey JM; Duh QY; Clark OH
    Cancer; 2001 Jun; 91(12):2335-42. PubMed ID: 11413523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
    Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
    Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting outcome and directing therapy for papillary thyroid carcinoma.
    Kim S; Wei JP; Braveman JM; Brams DM
    Arch Surg; 2004 Apr; 139(4):390-4; discussion 393-4. PubMed ID: 15078706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.